Abstract Number: 849 • 2017 ACR/ARHP Annual Meeting
Tumor TIF1 Mutations and Loss of Heterozygosity Related to Cancer Associated Myositis
Background/Purpose: To analyze the influence of genetic alterations and differential expression of the TIF1 genes in the pathophysiology of cancer-associated myositis (CAM). Methods: Whole exome…Abstract Number: 853 • 2017 ACR/ARHP Annual Meeting
Anti-TIF-1 Antibody Positivity Is Associated with a Five-Fold Increase in Cancer Risk in the Idiopathic Inflammatory Myopathies
Background/Purpose: There is an increased cancer risk associated with the idiopathic inflammatory myopathies (IIM). Studies have identified that positivity for the autoantibody against transcriptional intermediary…Abstract Number: 1146 • 2017 ACR/ARHP Annual Meeting
Associations between Gout and Cancer in an Nhanes Cohort
Background/Purpose: Gout is the most common inflammatory disease in the United States (US), affecting more than 4% of the population. Although uric acid (UA) can…Abstract Number: 26 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Factor Positivity Increases All-Cause and Cancer Mortality Risk in Korean Healthy Examinees: A Kangbuk Samsung Health Study
Background/Purpose: Several studies have reported increased overall mortality in association with rheumatoid factor (RF) in RA. However, the clinical significance including health outcomes of RF…Abstract Number: 330 • 2016 ACR/ARHP Annual Meeting
Safety of Denosumab in Postmenopausal Osteoporosis and in Cancer and Bone Metastase Treatment: A Systematic Review and Meta-Analysis
Background/Purpose: Denosumab is a RANK ligand antibody and the first biologic agent used for the treatment of post-menopausal osteoporosis (OP) and prevention of bone metastases…Abstract Number: 855 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Systemic Sclerosis and Breast Cancer and the Effects on Treatment Outcome
Background/Purpose: Breast cancer has been shown to be more prevalent in patients with systemic sclerosis (SSc) compared to that in the general population. A close…Abstract Number: 2000 • 2016 ACR/ARHP Annual Meeting
Incidence of Cancer in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept
Background/Purpose: Patients with a history of cancer were excluded from pivotal clinical trials evaluating biologics. Therefore, only registries can inform us on the incidence of…Abstract Number: 2304 • 2016 ACR/ARHP Annual Meeting
Decreased Occurrence of Colon Cancer Among Gout Patients: Assessment By Physician Diagnosis and Colonoscopy
Background/Purpose: The relationship between gout and cancer remains unclear. Whereas some studies have reported possible anti-cancer benefits of uric acid and monosodium urate crystals, others…Abstract Number: 2314 • 2016 ACR/ARHP Annual Meeting
Anti-Mi2 Dermatomyositis Revisited: Pure DM Phenotype with Muscle Fiber Necrosis and High Risk of Malignancy
Background/Purpose: Anti-Mi2 autoantibodies (Aabs) have been proposed to be highly specific for dermatomyositis (DM) and to be associated with a DM classical phenotype consisting of…Abstract Number: 2320 • 2016 ACR/ARHP Annual Meeting
Oropharyngeal Dysphagia in Autoimmune Myositis
Background/Purpose: Oropharyngeal dysphagia (OPD) is an ominous finding in autoimmune myositis (AIM), yet few studies have evaluated the disease subsets at higher risk for this…Abstract Number: 2447 • 2016 ACR/ARHP Annual Meeting
Does a History of Abnormal Pap Smear or Preceeding HPV Infection Affect Humoral Immune Response to Quadrivalent Human Papilloma Virus (qHPV) Vaccine in Women with Systemic Lupus Erythematosus (SLE)
Background/Purpose: Cervical neoplasia is increased in women with SLE. HPV types 16 & 18 account for 70% of cervical cancer. Natural HPV cervical infection generates…Abstract Number: 2629 • 2016 ACR/ARHP Annual Meeting
Serious Adverse Events in Patients with RA Taking Abatacept Compared with Other Dmards. Results from a US-Wide Safety Registry
Background/Purpose: Observational studies are critical in assessing medication safety and effectiveness in the real world. Nonrandom assignment can provide insight to how and when medications…Abstract Number: 2990 • 2016 ACR/ARHP Annual Meeting
Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort
Background/Purpose: Published studies of cancer risk in SLE to date have never focussed solely on clinically confirmed, incident patients. Prior studies thus may not reflect the cancer…Abstract Number: 3067 • 2016 ACR/ARHP Annual Meeting
Treatment Decisions Following Diagnosis of Cancer during TNFi Inhibitor Treatment in Patients with Rheumatoid Arthritis: Results from the BSRBR-RA
Treatment Decisions Following Diagnosis of Cancer During TNFi inhibitor Treatment in Patients with Rheumatoid Arthritis: results from the BSRBR-RA Druce KL, De Cock D, Watson…Abstract Number: 3080 • 2016 ACR/ARHP Annual Meeting
Rheumatologic Consequences of Immunotherapy to Treat Malignancies: The Tip of an Iceberg
Rheumatologic Consequences of Immunotherapy to Treat Malignancies: The Tip of an Iceberg Background/Purpose: Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed…